Skip to main content

COVID-19

 

Clinical courses

 

Clinical courses

  • A machine-learning approach to finding treatment options for Covid-19

    When the Covid-19 pandemic struck in early 2020, doctors and researchers rushed to find effective treatments. There was little time to spare. "Making new drugs takes forever," says Caroline Uhler, a computational biologist in MIT's Department of Electrical Engineering and Computer Science and the Institute for Data, Systems and Society, and an associate member of the Broad Institute of MIT and Harvard. "Really, the only expedient option is to repurpose existing drugs."

  • COVID WHO Investigation: A Smoke Screen for China

    Amid premature and incomplete reports from the World Health Organization’s (WHO) investigative team which has just concluded its work in China to discover the origins of SARS-CoV-2, AIDS Healthcare Foundation (AHF) calls for the investigation to continue and for the team to release a detailed report and hold a legitimate press conference after leaving China.

  • Phase 3 trial recruitment starts for COVID-19 vaccine of Janssen

    The University of Kentucky has been selected as a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 clinical research study ENSEMBLE 2, which is evaluating the safety and efficacy of a two-dose regimen of Janssen’s COVID-19 vaccine candidate.

  • India is also providing vaccines to neighboring countries

    In this difficult time when the whole world has suffered from an unknown, invisible and unknowable virus COVID-19, India is ready to provide its cut to the world community. India, which has become the Corona vaccine, is running the world's largest vaccination campaign today. Not only this, along with the vaccination of Corona to Indians, India is also providing vaccines to many other countries.

  • 21% of India’s adult population had COVID-19 by mid-December : Serological Survey

    According to the third national serological-survey report of the Indian Council of Medical Research (ICMR), over 21 percent of the population, aged 18 years and above, showed evidence of past exposure to COVID-19. The data on seroprevalenceamong those aged 10-17 was found to be 25.3 percent.

  • Bayer to manufacture mRNA vaccine in Germany

    In a joint press briefing today together with German Health Minister Jens Spahn, Minister-President of North Rhine-Westphalia, Armin Laschet, and Chief Executive Officer of CureVac N.V., Franz-Werner Haas, Member of the Board of Management, Bayer AG and President of the Bayer’s Pharmaceuticals Division, Stefan Oelrich, made the following statement  “Following discussions with the German government it has become clear that current manufacturing capacities for vaccines need to be increased, particularly for potential variants of the SARS-CoV-2 virus.

  • Private sector in COVID vaccination

    The private health sector is playing an important role in supplementing the activities of Government agencies in the on-going pan-India vaccination campaign to bring the COVID-19 pandemic under control.

  • CDSA Mission COVID Suraksha Project recruitment

    Translational Health Science and Technology Institute (THSTI) is an autonomous Institute of the Department of Biotechnology (DBT), Ministry of Science and Technology, Govt. of India. The institute is an integral part of the interdisciplinary NCR Biotech Science Cluster (NCR BSC) located at Faridabad, and is designed with the mission to conduct innovative translational research to translate concepts into products to improve human health.

  • Focus on management of adverse events in COVID-19 vaccination

    The operation guidelines prepared by the Central Government for the COVID-19 vaccination programme currently underway, provides a detailed roadmap to ensure a robust surveillance system to monitor adverse events post immunization and better understand the safety profile of the vaccines.

  • Inter-sectorial Convergence for COVID 19 vaccination

    As many as 19 Ministries and Departments of the Government of India are involved in the implementation of the national vaccination campaign that is currently underway to overcome the COVID-19 pandemic.

Subscribe to COVID-19